Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New technique could make cell-based immune therapies for cancer safer and more effective

17.12.2012
A team led by Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan-Kettering Cancer Center, has shown for the first time the effectiveness of a new technique that could allow the development of more-specific, cell-based immune therapies for cancer. Their findings were reported online today in Nature Biotechnology.

Immunotherapies — which make use of patients' own immune cells that have been augmented in the laboratory — have shown some early success in the treatment of blood cancers including certain types of leukemia.

For most cancers, however, cell-based therapies have been harder to develop, in large part because it has been difficult for investigators to train immune cells to specifically attack cancer cells without damaging normal, healthy cells in the body.

The treatment approach, known as adoptive cell transfer (ACT), involves engineering an immune cell called a T cell. In the ACT process, T cells are removed from a patient and a gene is added to allow the T cells to recognize a certain antigen on the surface of a cancer cell. The enhanced cells are grown in the laboratory and then infused back into the patient to seek out and attack cancer cells.

"We are getting better at working with these T cells and enhancing them so that we can get a powerful immunological response against cancer," Dr. Sadelain says. "The dilemma now is that we are concerned with limiting these responses and making them as targeted as possible to avoid potentially harmful side effects."

Cancer cells overproduce certain antigens, which can help T cells to recognize them, but those same antigens are often found in lower levels on healthy cells. "There are very few antigens, if any, that are found only on cancer cells," Dr. Sadelain explains.

"Now we are bringing in a completely new concept," he adds. "If there is no single unique antigen that is found on the surface of the cancer cell we want to target, we instead create T cells that recognize two different antigens found on the tumor cell — a signature that will be unique to that type of cancer — and only attack cells with both antigens, sparing the normal cells that express either antigen alone."

The new technique makes use of receptors known as chimeric antigen receptors (CARs), which allow T cells to target antigens on the surface of a tumor cell, coupled with another type of receptor called a chimeric costimulatory receptor (CCR), by which the T cells can recognize a second antigen.

The CAR and the CCR work together through a process known as balanced signaling, in which the presence of either antigen on its own is not enough to trigger the immune response. Only tumor cells that carry both antigens will be targeted.

In the Nature Biotechnology study, the team created T cells that carried a CAR for an antigen called PSMA and a CCR for an antigen called PSCA. Both PSMA and PSCA are found on prostate cancer cells. The investigators then generated mouse models of prostate cancer and infused the mice with the engineered cells. They found that the T cells attacked only tumors that carried antigens for both PSMA and PSCA.

"We are the first to test this concept and show that it works," Dr. Sadelain concludes. "We plan to develop clinical trials based on this approach, although we have not yet decided whether the first study will be a trial for prostate cancer or for a different type of cancer using two other antigens. Ultimately, our goal is to create targeted immunotherapies that are both potent and safe for patients."

In addition to members of Dr. Sadelain's laboratory, coauthors on the study included two researchers from TU Dresden in Germany.

This work was supported by philanthropic funds provided by the Mr. William H. and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research, the Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center, the Major Family Fund for Cancer Research at Memorial Sloan-Kettering, Mr. and Mrs. Joel S. Mallah, and Mr. Lewis Sanders.

Andrea Molinatti | EurekAlert!
Further information:
http://www.mskcc.org

More articles from Life Sciences:

nachricht Bats use the evening sky’s polarization pattern for orientation
22.07.2014 | Max Planck Institute for Ornithology, Seewiesen School of Biological Sciences, Queen’s University Belfast, UK

nachricht Oregon chemists eye improved thin films with metal substitution
22.07.2014 | University of Oregon

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

Event News

“Lens on Life” - Artists and Scientists Explore Cell Divison

08.07.2014 | Event News

First International Conference on Consumer Research | ICCR 2014: Early bird deadline July 31, 2014

08.07.2014 | Event News

First evidence for painless atrial fibrillation treatment

04.07.2014 | Event News

 
Latest News

Siemens installs two offshore platforms for TenneT in the North Sea in July

22.07.2014 | Press release

Hubble traces the halo of a galaxy more accurately than ever before

22.07.2014 | Physics and Astronomy

Quantum leap in lasers at Dartmouth brightens future for quantum computing

22.07.2014 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>